Sath Shukla - Feb 1, 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Financial Officer
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Sath Shukla
Stock symbol
SPRO
Transactions as of
Feb 1, 2023
Transactions value $
-$17,372
Form type
4
Date filed
2/3/2023, 06:41 PM
Previous filing
Aug 30, 2022
Next filing
Aug 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +266K +474.38% $0.00 322K Feb 1, 2023 Direct F1, F2
transaction SPRO Common Stock Sale -$17.4K -9.5K -2.95% $1.83 313K Feb 2, 2023 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Includes 312,518 RSUs held by the Reporting Person.
F3 The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
F4 Represents the weighted average sales price per share. The shares sold at prices ranging from $1.81 to $1.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.